A Game-Changing Discovery: Scientists Find New Ways to Treat Cataracts Without Surgery

Scientists have discovered two groundbreaking approaches that could treat cataracts without surgery, offering hope to millions who face vision loss from this common eye condition. The first involves a chelation-based eye drop that showed significant improvements in early cataract patients, while the second identifies a protein that can actually reverse lens cloudiness.

How Do These New Treatments Actually Work?

The first breakthrough comes from a Phase II clinical trial testing C-KAD, a 2.6% EDTA ophthalmic solution that works by removing heavy metals and accumulated materials from the eye's lens. Patients with early nuclear sclerosis and anterior cortical cataracts who used these drops showed statistically significant improvements in contrast sensitivity, equivalent to gaining approximately two lines of vision in low-light conditions.

The second discovery emerged from studying hibernating 13-lined ground squirrels at the National Institutes of Health (NIH). Researchers found that these animals develop cataracts during hibernation at cold temperatures, but their lenses clear up completely when they warm up. The key player is a protein called RNF114, which helps break down old, misfolded proteins that cause lens cloudiness.

What Were the Results From Human Testing?

The human trial results were particularly encouraging for people with specific types of early cataracts. The study included participants with early clinical nuclear sclerosis and anterior cortical cataracts, though it excluded those with posterior subcapsular cataracts. Over several months of treatment, patients experienced measurable improvements that were confirmed through both vision testing and advanced imaging techniques called Schiempflug imaging, which objectively demonstrated better lens clarity.

The treatment's safety profile was also reassuring, with researchers noting:

• Minimal Side Effects: Adverse effects were limited, with only mild ocular irritation reported slightly more frequently than in the placebo group
• Objective Improvements: Schiempflug imaging provided concrete evidence of lens clarity improvements beyond just patient-reported vision changes
• Lasting Benefits: While the trial didn't include long-term follow-up, anecdotal evidence suggests effects may persist for up to two years

"Scientists have long searched for an alternative to cataract surgery, which is effective, but not without risk. Lack of access to cataract surgery is a barrier to care in some parts of the world, causing untreated cataracts to be a leading cause of blindness worldwide," said Xingchao Shentu, M.D., a cataract surgeon and co-lead investigator from Zhejiang University, China.

What Questions Still Need Answers?

While these discoveries are promising, researchers acknowledge several important unknowns. The chelation-based treatment needs Phase III trials to establish its long-term durability and determine whether it could work as a preventive measure for people at risk of developing cataracts. The protein-based approach, while showing proof-of-principle success in animal models, requires extensive development before human testing can begin.

"Understanding the molecular drivers of this reversible cataract phenomenon might point us in a direction toward a potential treatment strategy," explained Wei Li, Ph.D., senior investigator in the NEI Retinal Neurophysiology Section. The research team developed innovative lab-based models using stem cells to study how RNF114 facilitates the breakdown of old proteins that cause cataracts.

Both treatments represent significant departures from traditional cataract management, which has relied exclusively on surgical lens replacement. The potential to delay or reduce the need for cataract surgery could have major implications for patient outcomes and healthcare accessibility, though pricing and widespread availability will ultimately determine how these innovations reach patients who need them most.